-
15th International T-Cell Lymphoma Forum丨Professor Wenyu Shi and Dr. Yi Miao: Application of EASIX in Predicting Survival of T/NK-LA HLH Patients
A research study led by Professor Wenyu Shi from the Affiliated Hospital of Nantong University and Dr. Yi Miao from The First Affiliated Hospital with Nanjing Medical University (Jiangsu Provincial Hospital), under the Jiangsu Lymphoma Collaboration Group and the Jiangsu HLH Working Group, was selected for an oral presentation. This study is the first to…
-
Immune Reconstitution Following CD7 CAR-T Therapy for Relapsed/Refractory Acute T-cell Lymphoblastic Leukemia/T-cell Lymphoblastic Lymphoma
From June 13 to 16, 2024, the 29th Annual Congress of the European Hematology Association (EHA) was held in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world every year to share and discuss innovative ideas and the latest scientific and…
-
EHA in 5 Minutes | Professor Huanling Zhu: SUSTRENIM Trial— Observational Study on Sustained Deep Molecular Response and Treatment-Free Remission
The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13-16, 2024, in Madrid, Spain. As the largest international event in the field of hematology in Europe, this conference attracts numerous renowned experts and scholars from around the world to share and discuss innovative concepts, the latest scientific research, and clinical…
-
ASCO 2024丨mRNA-4157 Vaccine Shows Long-Term Survival Benefits in Melanoma Treatment
mRNA cancer vaccines are an emerging cancer treatment strategy that uses mRNA technology to encode tumor-associated antigens, stimulating the patient’s immune system to fight cancer cells. With the successful application of mRNA technology in vaccine development, its role in cancer treatment is gaining increasing attention. mRNA-4157 is a novel personalized cancer vaccine that has shown…
-
ASCO 2024丨Impact of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 31 to June 4. Multiple research advancements in urologic oncology were presented, including the SWOG S1600 study results shared by Dr. Jill Hamilton-Reeves. This study explored the impact of immune-enhancing nutrition on the outcomes of radical cystectomy. Oncology Frontier…
-
JOH | Changes in Liver Stiffness Measurements Independently Associated with Liver-Related Events Risk in NAFLD Patients
Recently, Professor Naga P. Chalasani and his research team from Indiana University published a significant study online in the prestigious hepatology journal JOH. The study, titled “Increases and Decreases in Liver Stiffness Measurements are Independently Associated with the Risk of Liver-Related Events in NAFLD Patients,” was initiated by Professor Naga P. Chalasani in collaboration with…
-
ASCO 2024丨Liver Cancer Research Highlights: First-Line Immunotherapy “Double Star” Post-Immunotherapy Targeted Treatment, and CAR-T Therapy for Liver Cancer
The treatment of advanced hepatocellular carcinoma (HCC) has entered the era of targeted and immunotherapy, with combined regimens becoming the first-line standard. More combination therapies are still under exploration. At the recently concluded 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the CheckMate 9DW study announced positive results for the dual immunotherapy of anti-PD-L1…
-
ASCO International Perspective | Christos Kyriakopoulos: Results of the CHAARTED2 Study on Cabazitaxel Combined with Abiraterone for mCRPC
The CHAARTED study demonstrated that early use of chemotherapy combined with androgen deprivation therapy (ADT+docetaxel) significantly improves survival for most patients with metastatic hormone-sensitive prostate cancer (HSPC). However, most patients eventually develop castration-resistant prostate cancer (CRPC) and require additional systemic treatment. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Christos Kyriakopoulos…
Connecting Medical Expertise through Media